Dr. Awan Discusses Venetoclax in CLL
Farrukh Awan, MBBS
Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).
Venetoclax has been approved for relapsed patients with CLL who have a 17p deletion. As a single agent, it is very effective, potent, and induces deep remissions, says Awan.
Based on its success, it is starting to be tested in combinations.